These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 11858936)
1. PTEN: The down side of PI 3-kinase signalling. Leslie NR; Downes CP Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936 [TBL] [Abstract][Full Text] [Related]
2. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086 [TBL] [Abstract][Full Text] [Related]
8. Regulation of the PTEN phosphatase. Gericke A; Munson M; Ross AH Gene; 2006 Jun; 374():1-9. PubMed ID: 16675164 [TBL] [Abstract][Full Text] [Related]
9. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Meuillet EJ; Mahadevan D; Berggren M; Coon A; Powis G Arch Biochem Biophys; 2004 Sep; 429(2):123-33. PubMed ID: 15313215 [TBL] [Abstract][Full Text] [Related]
10. PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Weng LP; Brown JL; Baker KM; Ostrowski MC; Eng C Hum Mol Genet; 2002 Jul; 11(15):1687-96. PubMed ID: 12095911 [TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. Maehama T; Dixon JE J Biol Chem; 1998 May; 273(22):13375-8. PubMed ID: 9593664 [TBL] [Abstract][Full Text] [Related]
12. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles. Déléris P; Bacqueville D; Gayral S; Carrez L; Salles JP; Perret B; Breton-Douillon M J Biol Chem; 2003 Oct; 278(40):38884-91. PubMed ID: 12847108 [TBL] [Abstract][Full Text] [Related]
13. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Raftopoulou M; Etienne-Manneville S; Self A; Nicholls S; Hall A Science; 2004 Feb; 303(5661):1179-81. PubMed ID: 14976311 [TBL] [Abstract][Full Text] [Related]
14. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Steelman LS; Bertrand FE; McCubrey JA Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861 [TBL] [Abstract][Full Text] [Related]
15. PTEN: life as a tumor suppressor. Simpson L; Parsons R Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521 [TBL] [Abstract][Full Text] [Related]
16. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368 [TBL] [Abstract][Full Text] [Related]
17. PTEN and myotubularin: novel phosphoinositide phosphatases. Maehama T; Taylor GS; Dixon JE Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408 [TBL] [Abstract][Full Text] [Related]